

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 March 2004 (11.03.2004)

PCT

(10) International Publication Number
WO 2004/019901 A2

(51) International Patent Classification⁷: **A61K 9/00**

(21) International Application Number:
PCT/IB2003/003602

(22) International Filing Date: 29 August 2003 (29.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
640/MAS/2002 30 August 2002 (30.08.2002) IN

(71) Applicant (for all designated States except US): **ORCHID CHEMICALS & PHARMACEUTICALS LTD.**
[IN/IN]; Orchid Towers, 152 Village Road, Nungambakkam, 600034 Chennai (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KSHIRSAGAR, Rajesh, Suresh** [IN/IN]; Sree Lakshmi Apartments, 3rd Floor, Flat No. 1/11, 10th Cross Street, Shastrinagar, Adyar (IN). **DEVARAJAN, Sampath, Kumar** [IN/IN]; 15/2 Karani Garden,, IInd Street, Saidapet, 600015 Chennai (IN). **JINDAL, Kour, Chand** [IN/IN]; House No. 78, Sector - 9, Panchkula, 134113 Haryana (IN).

(74) Common Representative: **ORCHID CHEMICALS & PHARMACEUTICALS LTD.**; PADMAJA, S., R & D Centre, Plot No. 476/14, Sholinganallur, 600119 Chennai (IN).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION

(57) Abstract: The present invention relates to a sustained release oral pharmaceutical composition, having a beta lactam antibiotic or their pharmaceutically acceptable salts, hydrates or esters in a polymer mixture such that the beta lactam antibiotic is released over an extended period, suitable for once or twice daily oral administration. The invention preferably relates to a sustained release pharmaceutical composition of a beta lactam antibiotic having gelling tendency when in contact with the gastrointestinal fluids. The invention more preferably relates to sustained release pharmaceutical composition of prodrugs of cefpodoxime and cefuroxime such as cefpodoxime proxetil and cefuroxime axetil.



WO 2004/019901 A2

SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION

Field of the invention

The present invention relates to a sustained release pharmaceutical composition, having a beta lactam antibiotic or their pharmaceutically acceptable salts, hydrates or esters in a polymer mixture such that the beta lactam antibiotic is released over an extended period, suitable for once or twice daily oral administration. The invention preferably relates to a sustained release pharmaceutical composition of the beta lactam antibiotic having gelling tendency when in contact with the gastrointestinal fluids. The invention more preferably relates to sustained release pharmaceutical compositions of prodrugs of cefpodoxime and cefuroxime such as cefpodoxime proxetil and cefuroxime axetil.

Background of the Invention

While many compounds are known to be useful as pharmacologically active substances, some of them have relatively short biological half life and needs to be administered several times a day in order to achieve desired therapeutic effects. Especially, the drugs used in the treatment of microbial infections are required to be given more than once during a dosage regimen.

In an anti-microbial therapy the main requirement is to maximize the blood concentration, preferably several folds higher than the minimum inhibitory concentration (MIC) for the active agent, yet to minimize both the risk of toxicity to the patient and of promoting microbial resistance to the active agent. Although oral administration will be the preferred route, in the case of antibiotics this route is frequently unattractive because of their low or variable oral bioavailability. In addition extremely high plasma concentrations of antibiotics are frequently required to achieve the MIC values towards certain gram-negative bacteria (Antibiotics and Chemotherapy; Anti infective

agents and their use in therapy, 7th edition Ed. By O'grady F, Finch RG, Lambert HP; Greenwood D; Churchill Livingstone 1997).

Sustained release preparation of drugs are advantageous as the administration frequency can be reduced by maintaining a constant plasma concentration of drug over an extended period of time to ensure sustained effect of active ingredient well above the MIC levels. In addition, these preparations are also expected to decrease side effects by suppressing the rapid rise in the blood levels of the drugs.

This has been primarily achieved by development of a novel drug delivery system utilizing diverse techniques and principles. Amongst these, known in the art is one such delivery system, which employs hydrophilic polymers to sustained or modified release pharmaceutical composition. For modified release solid dosage forms comprising a drug dispersed uniformly in mixture of polymers, release of the drug is controlled primarily by diffusion of the drug, or by surface erosion of the hydrophilic polymers into the surrounding medium or by a combination of both processes. Control of the rate of release can produce constant blood levels of the active ingredient that may result in reducing the frequency of administration, thereby improving patient compliance to the dosage regimen.

The relevant prior art references, which disclose diverse delivery systems for the sustained release of the active ingredient, are summarized below.

United States Patent No.6,120,803 discloses an active agent dosage form, which is adapted for retention in the stomach and useful for the prolonged delivery of an active agent to a fluid environment of use. The active agent dosage form is a polymer matrix that swells upon contact with the fluid of the stomach. A portion of the polymer matrix is surrounded by a band of insoluble material that prevents the covered portion of the polymer matrix from swelling and provides a segment of the dosage form that is of sufficient

rigidity to withstand the contraction of the stomach and delay expulsion of the dosage form from the stomach until substantially all the active agent has been dispensed.

United States Patent No.5,128,142 discloses a controlled release formulation comprising an adsorbate of a mixture of a pharmaceutically useful active ingredient and an inactive substance adsorbed on a cross linked polymer. The inactive substance is selected to modify the dissolution of active ingredients from the cross-linked polymer *in vivo*. The inactive substance is preferably present in the adsorbate in an amount of 0.5 - 3 parts by weight relative to 1 part by weight of the active ingredients.

United States Patent No.4,968,508 discloses a sustained release matrix tablet comprising from about 0.1% to about 90% by weight of cefaclor, about 5% to about 29% by weight by hydrophilic polymer and about 0.5% to about 25% by weight of an acrylic polymer which dissolve at a pH in the range of about 5.0 to about 7.4, the total weight of polymers being less than 30% by weight of the formulation. Although a specific cefaclor formulation is claimed, the text suggests that the matrix formulation is suitable for weakly basic drugs and particularly suitable for cephalexin and cefaclor.

United States Patent No.5,948,440 discloses a controlled release tablet of an active ingredient comprising of cefaclor, cephalexin or their pharmaceutically acceptable hydrates, salts or esters as active ingredients and a mixture of hydrophilic polymers selected from the group consisting of at least one hydroxypropyl methylcellulose and at least one hydroxypropyl cellulose. The composition optionally also contains one or more of a water soluble or water dispersible diluent, the quantities are such that the therapeutically effective active ingredient is released at a rate suitable for twice daily administration of the pharmaceutical composition.

International Publication number WO00/15198 teaches controlled delivery pharmaceutical composition having temporal and spatial control, comprising a drug, a gas generating component, a swelling agent, a viscolyzing agent and optionally a gel forming polymer. The viscolyzing agent initially and the gel forming polymer thereafter form a hydrated gel matrix which entraps the gas, causing the tablet to float so that it is retained in the stomach thereby providing spatial control and at the same time resulting in sustained release of the drug providing temporal control. The combination of gas generating component, swelling agent and viscolyzing agent results in the controlled drug delivery systems. Thus all these components are essential for achieving the temporal and spatial control. A preferred once daily ciprofloxacin formulation comprising 69.9% ciprofloxacin base, 0.34% sodium alginate, 1.03% xanthan gum, 13.7% sodium bicarbonate, 12.1% cross linked polyvinyl pyrrolidone and optionally other excipients is disclosed.

International Publication number WO 02/41876 discloses a pharmaceutical composition in the form of a tablet for controlled release of an active ingredient comprising a beta lactam antibiotic such as cephalixin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters as active ingredients, and a mixture of hydrophilic polymers selected from the group consisting of at least one sodium alginate and at least one xanthan gum as controlled release matrix and optionally probenecid as an antibiotic adjuvant as either immediate release or controlled release part. The composition may contain one or more of a water-soluble and/or water dispersible diluent. The quantity of the hydrophilic polymer matrix still provides the desired once a day drug release profile.

United States Patent No.6,399,086 discloses a controlled release beta lactam antibiotic agent preferably amoxicillin trihydrate in a hydrophilic and/or hydrophobic polymer matrix such that at least 50% but not more than 67.61 ± 5.78 % of the active agent is released within 3-4 hrs from oral

administration and remainder is released at a controlled rate from the said composition. The composition teaches the use of commonly used hydrophilic polymers such as hydrophilic cellulose derivatives, hydrophilic methacrylic acid derivatives, chitosan, and alginates. Preferably, the use of hydrophilic cellulose derivative such as methylcellulose, hydroxypropyl methylcellulose, and hydroxyethyl cellulose, is disclosed. The hydrophobic polymers used in the invention are acrylamides and polyamido derivatives and hydrophobic methacrylic acid derivatives. The preferred hydrophobic polymer is ethyl cellulose. However, with this drug release profile wherein 67.61 ± 5.78 of the drug is already out of the matrix in 3-4 hrs and considering a very short half-life of both cefpodoxime proxetil and cefuroxime axetil of 2-3 hrs and about 1hr respectively, the composition may not be suitable for once daily administration. Hence, it is necessary that the matrix formulation should release the drug over extended period of time.

International Publication number WO 02/36126 discloses a fast disintegrating controlled release oral composition comprising a core material containing cefuroxime axetil present as controlled release form, the cefuroxime axetil being provided with an outer coating of a copolymer selected from aqueous dispersions of enteric methacrylic acid and methacrylic acid esters anionic copolymers having carboxyl group as the functional group or mixture thereof and an inner coating of a sustained release copolymer selected from aqueous dispersions of acrylate or methacrylate pH independent copolymers having quaternary ammonium group as a functional group or mixture thereof. Additionally the coating composition may contain plasticizers. The composition is suitable for once daily administration.

In multi-particulate controlled release dosage form the particles are less sensitive to the effect of gastric/stomach emptying time. As the particles are smaller, a portion of the particles gradually reaches the small intestine and passes small intestine relatively faster than the tablet dosage form even in the

presence of food. Hence, there is a potential chance of drug dissolution/delivery in the non-absorbable gastro-intestinal tract site. Therefore, there are chances for failure of the multi-particulate control release system especially if the drug has narrow absorption window in the gastro-intestinal tract. Cefuroxime axetil and cefpodoxime proxetil are reported to be absorbed from the upper part of the gastrointestinal tract. Hence, developing and achieving once daily administration through the multi-particulate controlled release system for the said drugs having absorption in upper part of GIT with short biological half-life, and the cumbersome process involved in developing such type of dosage form, makes it undesirable.

Cefpodoxime proxetil and cefuroxime axetil, are broad spectrum antibiotics active against both gram positive and gram negative microorganisms. Cefpodoxime proxetil and cefuroxime axetil oral bioavailability is reported to be 50%, with a slight increase in the bioavailability in the presence of food, and they are orally administered twice daily. Cefpodoxime proxetil and cefuroxime axetil molecules tend to form gels, upon exposure to the environmental fluids. These drugs form gel in contact with acidic media of the stomach, leading to reduction in dissolution and that, in turn, leads to poor bioavailability. Both cefuroxime axetil and cefpodoxime proxetil have narrow absorption window, i.e., absorbed less from the upper part of gastrointestinal tract, and at the same time, have plasma half-lives of 1.2 and 2.1 to 2.9 hrs, respectively.

The relevant prior arts, which describe the formulations to overcome the gelling of cefuroxime axetil, are as follows:

United States Patent No. 4,897,270 discloses a film coated cefuroxime axetil tablet to mask the bitter taste of the drug upon oral administration. The patent teaches that conventional film coated tablets result in low levels of absorption of cefuroxime axetil from gastrointestinal tract (GIT) and this is overcome by control of the film coat rupture time and use of a tablet core,

which disintegrates immediately following rupture of the film coat. The patent further teaches that cefuroxime axetil, once in contact with aqueous media, can form a gelatinous mass. This gelling effect is temperature dependent but does occur at temperature of about 37 °C, i.e., at the physiological temperature at which the disintegration of orally administered tablets takes place. The relatively slow permeation of moisture from the film coat to the core, which occurs upon administration of the tablets provided with conventional film coats, leads to gelling of cefuroxime axetil present in the core. The gel formation leads to poor disintegration of the tablet core and hence poor dissolution of cefuroxime axetil, thus the absorption from the GIT is greatly reduced. This occurs with both the crystalline and amorphous forms of cefuroxime axetil.

International Publication No. WO99/44614, however, comments that such thin film coating with the water soluble film-forming material cannot completely block the absorption of moisture into the core upon long term storage and thus rather may cause gelation of the active ingredient within the core of the tablet upon storage. The patent further claims a pharmaceutical composition comprising amorphous cefuroxime axetil and silicon dioxide or its hydrate as a micro environmental pH adjuster and an anti-gelling agent, which is not gelled by moisture absorption and is thus stable during storage period for cefuroxime axetil.

International Publication No. WO00/30647 discloses cefuroxime axetil in non-gelatinous form on contact with an aqueous liquid comprising cefuroxime axetil in the form of a solid solution in a polymer or in the form of a solid dispersion on an adsorbent, useful for pharmaceutical composition. The composition disclosed is a conventional formulation and it does not relate to a method to prevent the gelation of cefuroxime axetil if exposed to aqueous liquid for extended period of more than 45 minutes.

United States Patent No. 6,323,193 discloses that addition of sodium citrate to the formulation containing amorphous cefuroxime axetil, inhibits the tendency of amorphous cefuroxime axetil to form a gel. This may be due to the presence of citrate ions, which prevents cefuroxime axetil molecules from bridging with each other to form a gel, thereby helping in the tablet dissolution.

United States Patent No. 4,865,851 discloses cefuroxime axetil composition comprising particulate cefuroxime axetil coated with an integral coating of a lipid or mixture of lipids which are insoluble in water and which serves to mask the bitter taste of cefuroxime axetil but disperses or dissolves on contact with gastro-intestinal fluid. The resulting particles can be incorporated into pharmaceutical compositions for oral administration, for example aqueous suspension, dry product for reconstitution with water or granules. However, the drawback of this composition is that, coated particles having diameter of less than 250 microns are preferred and, the coating procedure employed is rather elaborate, resulting in the process which is inconvenient for preparing solid dosage forms of cefuroxime axetil for oral administration.

International Publication No. WO99/62559 discloses a pharmaceutical tablet comprising cefuroxime axetil and a carbonate to enhance the rate of disintegration of the tablets in gastric fluid.

International Publication No. WO99/08683 discloses a pharmaceutical composition comprising of co-precipitate of cefuroxime axetil and a water soluble excipient selected from the group consisting of povidone, hydroxypropyl cellulose, methyl cellulose, lactose, mannitol and sorbitol. Tablets made from the said co-precipitate exhibit high bioavailability without requiring that the tablets disintegrate immediately in gastro-intestinal fluid.

In the above prior art references, attempts have been made to overcome the gelling tendency of cefuroxime axetil for rapid release of the drug in the gastro-intestinal tract. However, the compositions described above cannot be used for controlled release of the drug to achieve and sustain therapeutic blood
5 levels for a prolonged period of time.

Most of the polymers used to prepare sustained release polymeric matrix dosage form, has a tendency to swell in the presence of water and form gel like consistency. When this happens, the gel provides a natural barrier for drug diffusion through the swollen, hydrated gelled layer, in addition to the
10 erosion from the surface of the tablet. Since the gel like material is quite viscous and may not disperse for hours, this provides a means of sustaining the drug release for extended hours until all the drug has been dissolved and diffused out in to the intestinal fluid. Similarly, the plastic matrix provides a rapid geometric surface for drug diffusion so that a relatively constant rate of
15 drug release is obtained.

Ideally, a sustained release dosage form should deliver the medicament at a constant rate throughout the GIT. However this cannot be helpful for beta lactam antibiotics, as they have a narrow absorption window, instability in higher pH and some of the beta lactam antibiotics also forms gel upon
20 exposure to the GIT fluids. A decline in the solubility due to gel formation in response to pH fluctuations within the body may result in a decreased release rate and thus poor bioavailability. Hence it is a very difficult task to develop a sustained release dosage form in the form of matrix tablets for drugs like cefuroxime axetil and cefpodoxime proxetil, which form gelatinous mass upon
25 contact with the environmental fluids.

The sustained release matrix form may be retained in the stomach for a long time due to the size of the dosage form and delayed stomach emptying time in the presence of food. Stomach emptying is particularly important in

the preparation of sustained release formulation for drugs having narrow absorption window.

Sustained release preparations of drugs are advantageous since the frequency of dosing can be reduced by maintaining a constant plasma concentration of drug over an extended period of time to ensure sustained effect of active ingredient.

Polymer blends in sustained release compositions are known and used in the pharmaceutical industry because of the blend versatility of being able to create different release properties. Polysaccharides such as carrageenans are desirable biopolymers for use in sustained release compositions because they are derived from naturally occurring seaweeds.

None of the prior art references teach about sustained release polymeric matrix tablets of drugs having gelling tendency when in contact with gastrointestinal fluids such as cefpodoxime proxetil or cefuroxime axetil, thus a need exists for such a composition wherein the active ingredient is released in a sustained manner maintaining above the effective plasma levels such that the dosage form is suitable for once or twice daily administration and thereby improving the patient compliance to the dosage regimen.

Although the antibiotics often require high dose and/or higher frequency of administration, extended release drug delivery systems have not been very successful in reducing the frequency. The present invention is based on the observation that the release of active ingredient from the delivery system is controlled by the specific polymers present in the matrix and in specific concentrations, thus allowing blood levels above MIC over extended period of time such that the frequency of the dosage form can be reduced to twice daily or once daily dosing. We have found surprisingly that when we combined the copolymers and a release enhancer along with a biopolymer, the gelling characteristics of the active ingredient was eliminated, and we could

achieve a constant release of the drug in-vitro over a extended period of time both in acidic and alkaline pH.

Objective of the Invention

The main objective of the present invention is to provide an oral
5 sustained release formulation of a beta lactam antibiotic or their
pharmaceutically acceptable salts, hydrates or esters.

Further objective of the present invention is to provide an oral sustained
release formulation for beta lactam antibiotic or their pharmaceutically
acceptable salts, hydrates or esters, having gelling tendency when in contact
10 with gastro-intestinal fluids.

Further objective of the present invention is to avoid gelling of beta
lactam antibiotic on contact with the gastro-intestinal fluid, yet controlling the
release of the beta lactam antibiotic or their pharmaceutically acceptable salts,
hydrates or esters in a non disintegrating matrix such that it provides
15 therapeutically effective blood levels of the medicaments for prolonged period
suitable for twice or once daily administration.

Summary of the Invention

The present invention provides a sustained release oral pharmaceutical
composition comprising a beta lactam antibiotic or their pharmaceutically
20 acceptable salts, hydrates or esters; mixture of polymers comprising of a water
soluble N-vinyl-2-pyrrolidone/vinyl acetate copolymer and polysaccharide(s);
a release enhancer(s); and other pharmaceutically acceptable excipients.

In an embodiment of the present invention the polysaccharide is
selected from different grades of carrageenan, used either alone or in
25 combination thereof.

In an embodiment of the present invention the pharmaceutical
composition is a solid dosage form, preferably in the form of a tablet.

In an embodiment of the present invention the pharmaceutical composition comprises from about 25 to 90% by weight of beta lactam antibiotic or their pharmaceutically acceptable salts, hydrates or esters.

5 In an embodiment of the present invention the pharmaceutical composition comprises of a mixture of polymers from about 1 to 35% by weight of the composition.

In an embodiment of the present invention the pharmaceutical composition comprises from about 1 to 30% of N-vinyl-2-pyrrolidone/vinyl acetate copolymer by weight of the composition.

10 In an embodiment of the present invention the pharmaceutical composition comprises from about 0.5 to 20% of carrageenan(s) by weight of the composition.

In an embodiment of the present invention the pharmaceutical composition comprises drug release enhancers from about 0.1 to 25% by weight of the total weight of the composition, used either alone or in combination.

In an embodiment of the present invention the pharmaceutically acceptable excipients are selected from integrity enhancers, disintegrants, solubilizers, lubricants, diluents, coating agents, and optionally binders.

20 In an embodiment of the present invention the pharmaceutical composition comprises from about 0.1 to 10% of integrity enhancers by weight of the composition.

In an embodiment of the present invention the pharmaceutical composition comprises from about 0.1 to 15% of disintegrant by weight of the composition.

25 In an embodiment of the present invention the pharmaceutical composition comprises from about 0.1 to 10% of solubilizer by weight of the composition.

In an embodiment of the present invention the pharmaceutical composition comprises of lubricant from about 0.2 % to about 5% by weight of the total weight of the composition, used either alone or in combination .

5 In an embodiment of the present invention the pharmaceutical composition comprises one or more pharmaceutically acceptable diluents in an amount from about 1 to about 40% by weight of the composition.

In an embodiment of the present invention the pharmaceutical composition comprises from about 0.1 to 20% of binder by weight of the composition.

10 In an embodiment of the present invention the pharmaceutical composition in the form of tablets are coated using conventional coating agents.

According to the present invention, the pharmaceutical composition may be prepared by dry granulation using the following procedure.

- 15 (i) blending the beta lactam antibiotic or its pharmaceutically acceptable salts, hydrates or esters, diluent(s) and copolymer; polysaccharide(s), disintegrant(s) and lubricant(s) either whole or in part; release enhancer(s), optionally integrity enhancer(s) and solubilizer(s) together,
- (ii) passing the blended mixture through a suitable sieve,
- 20 (iii) compacting the blend using a roller compactor,
- (iv) sizing the compacted material using a suitable mill,
- (v) blending the resultant granules with lubricant(s) in whole or in part; optionally with polysaccharide(s), release enhancer(s), and integrity enhancer(s), in whole or in part,
- 25 (vi) compressing the lubricated granules using a tableting machine and,
- (vii) coating the tablets.

In another embodiment of the present invention, the process for the preparation of the sustained release pharmaceutical composition, comprises the steps of:

- (i) blending the beta lactam antibiotic or their pharmaceutically acceptable salts, hydrates or esters, diluent(s), copolymer and polysaccharide(s); disintegrant(s) and lubricant(s) either whole or in part; release enhancer(s), optionally integrity enhancer(s) and solubilizer(s) together,
- 5 (ii) passing the blended mixture through a suitable sieve,
- (iii) compacting the blend using a roller compactor,
- (iv) sizing the compacted material using an suitable mill,
- (v) resultant granules coated with ethyl cellulose in a suitable fluid bed processor,
- 10 (vi) optionally sizing the coated granules by passing through a suitable sieve,
- (vii) blending the resultant granules with lubricant(s) and disintegrant(s),
- (viii) compressing the lubricated granules using a tableting machine and,
- (ix) coating the tablets.

15 Detailed Description of the Invention

According to the present invention the beta lactam antibiotic include amoxycillin, ampicillin, cephalixin, cefprozil, cefadroxil, cefaclor, cefamandole, cefoxitin, cephalothin, cephapirin, ceftizoxime, cefonicid, cefpodoxime proxetil, cefuroxime axetil, cefotiam hexetil, cefteram pivoxil,
20 cefditoren pivoxil, cefcapene pivoxil, cefetamet pivoxil or their pharmaceutically acceptable salts, hydrates or esters.

Preferably, the beta lactam antibiotic is in the form of a prodrug ester such as cefpodoxime proxetil, cefuroxime axetil, cefotiam hexetil, cefteram pivoxil, cefditoren pivoxil, cefcapene pivoxil or cefetamet pivoxil.

25 More preferably, the beta lactam antibiotic is selected from cefpodoxime proxetil or cefuroxime axetil.

According to another embodiment of the present invention the beta lactam antibiotic can be optionally combined with a beta lactamase inhibitor in a sustained release composition. The examples of such beta lactamase

inhibitors include clavulonic acid, sulbactam, tazobactam or their pharmaceutically acceptable salts, hydrates or esters.

Carrageenan is a naturally occurring family of polysaccharides extracted from red seaweed. It is a high molecular weight polysaccharide made up of repeating galactose and 3,6 anhydrogalactose (3,6-AG) units, both sulfated and nonsulfated. The units are joined by alternating alpha 1-3 and beta 1-4 glycosidic linkages. Three types of carrageenan are commercially available. They are iota, kappa and lambda. The primary differences which influence the properties of kappa, iota and lambda carrageenan are the number and position of the ester sulfate groups on the repeating galactose units. Higher levels of ester sulfate, lower the solubility and produce lower strength gels, or contribute to gel inhibition. All three types are soluble in hot water. Lambda is soluble in cold water whereas iota and kappa are insoluble, but their sodium salt is soluble in cold water. According to the present invention carrageenan used is selected from Viscarin GP328, Viscarin GP 209, and Gelcarin GP911 (FMC).

N-vinyl-2-pyrrolidone and vinyl acetate is a synthetic water-soluble copolymer in a random 60:40 ratio (copolyvidonum). Copolyvidonum is a highly effective film forming adhesive, the k-value for which is specified between 25.4 and 34.2. The copolymer that may be used in the present invention include Plasdone S-630 (ISP) or Kollidon VA64 (BASF).

According to our observation, when N-vinyl-2-pyrrolidone and vinyl acetate copolymer alone was used as matrix forming agent, the initial release of the cefpodoxime proxetil or cefuroxime axetil was higher and almost 100% of drug is released in first hour in acidic media. This is due to faster erosion of tablet because of water-soluble N-vinyl-2-pyrrolidone and vinyl acetate copolymer, which in turn dissolves the drug and gives higher drug release in the initial hour itself. Hence, incorporation of a polymer for controlling the release was desired. The cephalosporins have pH dependent solubility; they

have high solubility in acidic pH, which decrease with increase in pH. Hence, the polymer must have low solubility in acidic environment but dissolves relatively faster in the pH 6.8. Due to the inherent gelling tendency of some cephalosporins such as cefuroxime axetil or cefpodoxime proxetil, the polymer should not form strong gel, but sufficient to keep the integrity of the tablet throughout the gastro-intestinal tract. A polysaccharide such as carrageenan was incorporated along with N-vinyl-2-pyrrolidone and vinyl acetate copolymer, the initial release was controlled, but the release retarded in the later stages for both cefuroxime axetil and cefpodoxime proxetil.

Surprisingly, we found that, when we incorporated a release enhancing agent such as sodium chloride or lactose to the above composition the release was controlled initially and uniformly over extended period. It was also found out that there was no gelling of cefuroxime axetil or cefpodoxime proxetil in such composition.

Hence, in the present invention, the N-vinyl-2-pyrrolidone/vinyl acetate copolymer, carrageenan and sodium chloride or lactose when used in appropriate concentrations achieves a sustained release of the active ingredient over a extended period thereby achieving desired blood levels suitable for twice or once daily dosage regimen. In addition, the gelling tendency of beta lactam antibiotic was also eliminated.

In an embodiment of the present invention the pharmaceutical composition comprises release enhancer such as sodium chloride, potassium chloride; sulfates of sodium, potassium, calcium, magnesium; lactose or the like, used either alone or in combinations thereof.

In an embodiment of the present invention the pharmaceutical composition comprises integrity enhancers such as polyacrylic acid derivatives e.g. Carbopol 971P, Carbopol 974P, Novenon AA1, or the like, used either alone or in combinations thereof.

In an embodiment of the present invention the pharmaceutical composition comprises of water soluble or water dispersible diluents.

In an embodiment of the present invention the water soluble diluents are selected from mannitol, glucose, sorbitol, maltose, dextrans, dextrins and the like, used either alone or in combinations thereof.

In an embodiment of the present invention the water dispersible diluents are selected from carboxymethyl cellulose, calcium carboxymethyl cellulose, microcrystalline cellulose, pregelatinized starch, and the like, used either alone or in combinations thereof.

In an embodiment of the present invention the pharmaceutical composition comprises of the lubricant such as talc, stearic acid, magnesium stearate, colloidal silicon dioxide, calcium stearate, zinc stearate, hydrogenated vegetable oil, and the like, used either alone or in combinations thereof.

In an embodiment of the present invention the pharmaceutical composition comprises of binders such as cellulosic ether like methyl cellulose, hydroxy propyl cellulose, hydroxy ethyl cellulose, hydroxy propyl methyl cellulose or ethyl cellulose, polyvinyl pyrrolidone and its derivatives or copolymers; used either alone or in combinations thereof.

In an embodiment of the present invention the pharmaceutical composition comprises of disintegrant such as croscarmellose sodium (Acdisol), crospovidone, calcium carboxymethyl cellulose, sodium starch glycolate, and the like, used either alone or in combinations thereof.

In an embodiment of the present invention the pharmaceutical composition comprises of solubilizer such as cationic surfactants like cetrimide, benzalkonium chloride, benzethonium chloride; anionic surfactants like sodium lauryl sulphate, docusate sodium; and non-ionic surfactants like glyceryl monooleate, polyoxyethylene sorbitan fatty acid, polyoxyethylene sorbitan fatty esters, polyvinyl alcohol or sorbitan esters, used either alone or in combinations thereof.

In an embodiment of the present invention the pharmaceutical composition in the form of tablets are coated with coating agents such as Opadry (Colorcon).

In an embodiment of the present invention the coating agent may
5 comprise of film forming agents such as hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose; plasticizers such as propylene glycol, polyethylene glycol; color pigments; opacifiers such as titanium dioxide; and optionally talc.

Examples

10 The present invention is illustrated by the following examples, which are not intended to limit the scope of the invention, but are provided by way of illustration only.

In all the examples mentioned, the coating agent comprises of an aqueous dispersion of hydroxypropyl methylcellulose, propylene glycol, and
15 color pigment.

The procedure for carrying out the dissolution study for Cefpodoxime proxetil and Cefuroxime axetil is given below.

Procedure for the dissolution study for formulations of Cefpodoxime proxetil

The prepared cefpodoxime proxetil sustained release tablets were tested for cefpodoxime proxetil in 900 ml of pH 3.0 glycine buffer for 1 hr, after which the dissolution media was changed to pH 6.8 phosphate buffer 900ml every
70 hour up to 6 hrs. The tablets were placed in the dissolution vessel (USP type 2) and rotated at 75rpm.

Procedure for the dissolution study for formulations of Cefuroxime axetil

The prepared cefuroxime axetil sustained release tablets were tested for cefuroxime axetil in 900 ml of 0.07N hydrochloric acid in water for 1 hr, after
75 which the dissolution media was changed to pH 6.8 phosphate buffer 900 ml every hour up to 7 hrs. The tablets were placed in the dissolution vessel (USP type 2) and rotated at 75rpm.

Example 1Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefpodoxime proxetil (Equiv. to 400 mg cefpodoxime)	537.00	57.13
Calcium carboxymethyl cellulose	66.25	7.05
Croscarmellose sodium	25.00	2.66
Sodium lauryl sulfate	20.00	2.13
Lactose anhydrous	141.75	15.08
Plasdone S-630	50.00	5.32
Viscarin GP328	90.00	9.57
Magnesium stearate	10.00	1.06

Procedure for making the formulation

- 5 Cefpodoxime proxetil, calcium carboxymethyl cellulose, croscarmellose sodium, sodium lauryl sulfate, lactose anhydrous, Plasdone S-630, and Viscarin GP328, were screened through 40 mesh sieve and roll compacted. The compacts were crushed and passed through 20 mesh to get granules. The granules were blended with magnesium stearate. The lubricated granules were
- 10 then compressed into the tablets using a tablet press. The tablets were coated.

Example 2Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefpodoxime proxetil (Equiv. to 400 mg cefpodoxime)	537.00	57.13
Calcium carboxymethyl cellulose	66.25	7.05
Croscarmellose sodium	25.00	2.66
Sodium lauryl sulfate	20.00	2.13

Lactose anhydrous	136.75	14.55
Plasdone S-630	50.00	5.32
Viscarin GP328	90.00	9.57
Carbopol 971P	5.00	0.53
Magnesium stearate	10.00	1.06

Example 3Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefpodoxime proxetil (Equiv. to 400 mg cefpodoxime)	537.00	57.28
Calcium carboxymethyl cellulose	66.25	7.07
Croscarmellose sodium	25.00	2.67
Sodium lauryl sulfate	20.00	2.13
Lactose anhydrous	136.75	14.59
Plasdone S-630	50.00	5.33
Viscarin GP328	90.00	9.60
Carbopol 971P	2.50	0.27
Magnesium stearate	10.00	1.06

5 **Example 4**Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefpodoxime proxetil (Equiv. to 400 mg cefpodoxime)	537.00	57.13
Calcium carboxymethyl cellulose	66.25	7.05
Croscarmellose sodium	25.00	2.66
Sodium lauryl sulfate	20.00	2.13

Lactose anhydrous	131.75	14.02
Plasdone S-630	50.00	5.32
Viscarin GP328	90.00	9.57
Carbopol 971P	10.00	1.06
Magnesium stearate	10.00	1.06

Procedure for making the formulations of examples 2-4

Cefpodoxime proxetil, calcium carboxymethyl cellulose, croscarmellose sodium, sodium lauryl sulfate, lactose anhydrous, Plasdone S-630, Viscarin GP328, and Carbopol 971P, were screened through 40 mesh sieve and roll compacted. The compacts were crushed and passed through 20 mesh to get granules. The granules were blended with magnesium stearate. The lubricated granules were then compressed into the tablets using a tablet press. The tablets were coated.

Example 5

Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefpodoxime proxetil (Equiv. to 400 mg cefpodoxime)	564.0	60.30
Lactose anhydrous	141.7	15.16
Croscarmellose sodium	25.0	2.67
Calcium carboxymethyl cellulose	69.6	7.44
Sodium lauryl sulphate	20.0	2.14
Carbopol 971P	10.0	1.07
Plasdone S-630	50.0	5.35
Gelcarin GP911	25.0	2.67
Viscarin GP209	25.0	2.67
Magnesium stearate	5.0	0.53

Procedure for making the formulation

Cefpodoxime proxetil, calcium carboxymethyl cellulose, croscarmellose sodium, sodium lauryl sulfate, lactose anhydrous, Plasdone S-630, Viscarin GP209, Carbopol 971P, and Gelcarin GP 911, were screened through 40 mesh sieve and roll compacted. The compacts were crushed and passed through 20 mesh to get granules. The granules were blended with magnesium stearate. The lubricated granules were then compressed into the tablets using a tablet press. The tablets were coated.

Dissolution profile

<i>Time (hour)</i>	<i>Percent Cefpodoxime proxetil released</i>
1	29.20
2	56.00
3	74.70
4	89.65

10

Example 6Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefpodoxime proxetil (Equiv. to 400 mg cefpodoxime)	564.0	59.04
Lactose anhydrous	141.7	14.87
Croscarmellose sodium	25.0	2.61
Calcium carboxymethyl cellulose	69.6	7.28
Sodium lauryl sulphate	20.0	2.09
Plasdone S-630	50.0	5.23
Viscarin GP209	15.0	1.57
Lubrication Stage		
Gelcarin GP911	60.0	6.28

Carbopol 971P	5.0	0.52
Magnesium stearate	5.0	0.52

Procedure for making the formulation

Cefpodoxime proxetil, calcium carboxymethyl cellulose, croscarmellose sodium, sodium lauryl sulfate, lactose anhydrous, Plasdone S-630, and Viscarin GP209, were screened through 40 mesh sieve and roll compacted. The compacts were crushed and passed through 20 mesh to get granules. The granules were blended with Gelcarin GP911, Carbopol 971P, and magnesium stearate. The lubricated granules were then compressed into the tablets using a tablet press. The tablets were coated.

10 **Example 7**

Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefpodoxime proxetil (Equiv. to 400 mg cefpodoxime)	563.42	56.34
Lactose anhydrous	91.58	9.16
Plasdone S-630	50.00	5.00
Gelcarin GP911	30.00	3.00
Magnesium stearate	5.00	0.50
Ethyl cellulose	100.00	10.00
Lubrication Stage		
Calcium carboxymethyl cellulose	50.00	5.00
Croscarmellose sodium	100.00	10.00
Magnesium stearate	10.00	1.00

Procedure for making the formulation

Cefpodoxime proxetil, lactose anhydrous, Plasdone S-630, Gelcarin GP911, and, magnesium stearate, were screened through 40 mesh sieve and roll

compacted. The compacts were crushed and passed through 20 mesh to get granules. The resultant granules were coated with ethyl cellulose aqueous dispersion in a fluid bed processor. The resultant dried granules were screened and blended with calcium carboxymethyl cellulose, croscarmellose sodium, and magnesium stearate. The lubricated granules were then compressed into the tablets using a tablet press. The tablets were coated.

Dissolution profile

<i>Time (hour)</i>	<i>Percent Cefpodoxime proxetil released</i>
1	50.5
2	68.9
3	78.1
4	87.4

Example 8

Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefpodoxime proxetil (Equiv. to 400 mg cefpodoxime)	563.42	56.34
Lactose anhydrous	141.58	14.16
Plasdone S-630	50.00	5.00
Gelcarin GP911	30.00	3.00
Magnesium stearate	5.00	0.50
Ethyl cellulose	100.00	10.00
Lubrication Stage		
Croscarmellose sodium	100.00	10.00
Magnesium stearate	10.00	1.00

Procedure for making the formulation

Cefpodoxime proxetil, lactose anhydrous, Plasdone S-630, Gelcarin GP911, and, magnesium stearate, were screened through 40 mesh sieve and roll compacted. The compacts were crushed and passed through 20 mesh to get granules. The resultant granules were coated with ethyl cellulose aqueous dispersion in a fluid bed processor. The resultant dried granules were screened and blended with croscarmellose sodium, and magnesium stearate. The lubricated granules were then compressed into the tablets using a tablet press. The tablets were coated.

10 **Example 9**Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefpodoxime proxetil (Equiv. to 400 mg cefpodoxime)	563.42	56.34
Lactose anhydrous	61.58	6.16
Croscarmellose sodium	30.00	3.00
Plasdone S-630	50.00	5.00
Gelcarin GP911	30.00	3.00
Magnesium stearate	5.00	0.50
Ethyl cellulose	100.00	10.00
Lubrication Stage		
Calcium carboxymethyl cellulose	50.00	5.00
Croscarmellose sodium	100.00	10.00
Magnesium stearate	10.00	1.00

Procedure for making the formulation

Cefpodoxime proxetil, lactose anhydrous, croscarmellose sodium, Plasdone S-630, Gelcarin GP911, and, magnesium stearate, were screened through 40 mesh sieve and roll compacted. The compacts were crushed and passed

through 20 mesh to get granules. The resultant granules were coated with ethyl cellulose aqueous dispersion in a fluid bed processor. The resultant dried granules were screened and blended with calcium carboxymethyl cellulose, croscarmellose sodium, and magnesium stearate. The lubricated granules were then compressed into the tablets using a tablet press. The tablets were coated.

Example 10

Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefpodoxime proxetil (Equiv. to 400 mg cefpodoxime)	563.42	56.34
Lactose anhydrous	61.58	6.16
Calcium carboxymethyl cellulose	30.00	3.00
Plasdone S-630	50.00	5.00
Gelcarin GP911	30.00	3.00
Magnesium stearate	5.00	0.50
Ethyl cellulose	100.00	10.00
Lubrication Stage		
Calcium carboxymethyl cellulose	50.00	5.00
Croscarmellose sodium	100.00	10.00
Magnesium stearate	10.00	1.00

Procedure for making the formulation

Cefpodoxime proxetil, lactose anhydrous, calcium carboxymethyl cellulose, Plasdone S-630, Gelcarin GP911, and, magnesium stearate, were screened through 40 mesh sieve and roll compacted. The compacts were crushed and passed through 20 mesh to get granules. The resultant granules were coated with ethyl cellulose aqueous dispersion in a fluid bed processor. The resultant dried granules were screened and blended with calcium carboxymethyl cellulose, croscarmellose sodium, and magnesium stearate. The lubricated

granules were then compressed into the tablets using a tablet press. The tablets were coated.

Example 11

Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefpodoxime proxetil (Equiv. to 400 mg cefpodoxime)	563.42	56.34
Lactose anhydrous	116.58	11.66
Plasdone S-630	50.00	5.00
Gelcarin GP911	30.00	3.00
Magnesium stearate	5.00	0.50
Ethyl cellulose	75.00	7.50
Lubrication Stage		
Calcium carboxymethyl cellulose	50.00	5.00
Croscarmellose sodium	100.00	10.00
Magnesium stearate	10.00	1.00

5

Procedure for making the formulation

Cefpodoxime proxetil, lactose anhydrous, Plasdone S-630, Gelcarin GP911, and, magnesium stearate, were screened through 40 mesh sieve and roll compacted. The compacts were crushed and passed through 20 mesh to get granules. The resultant granules were coated with ethyl cellulose aqueous dispersion in a fluid bed processor. The resultant dried granules were screened and blended with calcium carboxymethyl cellulose, croscarmellose sodium, and magnesium stearate. The lubricated granules were then compressed into the tablets using a tablet press. The tablets were coated.

15

Examples 12Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefuroxime axetil (Equiv. to 400 mg cefuroxime)	600.0	46.88
Calcium carboxymethyl cellulose	354.0	27.66
Sodium lauryl sulfate	9.0	0.70
Sodium chloride	87.5	6.82
Plasdone S-630	200.0	15.63
Viscarin GP328	12.5	0.97
Hydrogenated vegetable oil	17.0	1.34

Examples 135 Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefuroxime axetil (Equiv. to 400 mg cefuroxime)	600.0	46.44
Calcium carboxymethyl cellulose	354.0	27.40
Sodium lauryl sulfate	9.0	0.69
Sodium chloride	87.5	6.75
Plasdone S-630	200.0	15.48
Viscarin GP328	25.0	1.93
Hydrogenated vegetable oil	17.0	1.31

Examples 14Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefuroxime axetil	600.00	47.81

(Equiv. to 400 mg cefuroxime)		
Calcium carboxymethyl cellulose	354.00	28.21
Sodium lauryl sulfate	9.00	0.72
Sodium chloride	62.25	4.96
Plasdone S-630	200.00	15.94
Viscarin GP328	12.50	1.00
Hydrogenated vegetable oil	17.00	1.35

Example 15Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefuroxime axetil (Equiv. to 400 mg cefuroxime)	600.00	47.36
Calcium carboxymethyl cellulose	354.00	27.93
Sodium lauryl sulfate	9.00	0.71
Sodium chloride	74.75	5.89
Plasdone S-630	200.00	15.78
Viscarin GP328	12.50	0.99
Hydrogenated vegetable oil	17.00	1.34

5 Dissolution profile

<i>Time (hour)</i>	<i>Percent Cefuroxime axetil released</i>
1	38.84
2	70.27
4	95.07
7	98.20

Procedure for making the formulations of examples 12-15

Cefuroxime axetil, calcium carboxymethyl cellulose, sodium lauryl sulfate, sodium chloride, Plasdone S-630, and Viscarin GP328, were screened through 40 mesh sieve and roll compacted. The compacts were crushed and passed through 20 mesh to get granules. The granules were blended with hydrogenated vegetable oil. The lubricated granules were then compressed into the tablets using a tablet press. The tablets were coated.

Example 16Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefuroxime axetil (Equiv. to 400 mg cefuroxime)	617.55	51.46
Lactose anhydrous	168.45	14.04
Plasdone S-630	60.00	5.00
Gelcarin GP911	36.00	3.00
Hydrogenated vegetable oil	6.00	0.50
Ethyl cellulose	120.00	10.00
Lubrication Stage		
Calcium carboxymethyl cellulose	60.00	5.00
Croscarmellose sodium	120.00	10.00
Hydrogenated vegetable oil	12.00	1.00

10

Example 17Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefuroxime axetil (Equiv. to 400 mg cefuroxime)	617.55	49.01
Lactose anhydrous	168.45	13.37

Plasdone S-630	60.00	4.76
Gelcarin GP911	36.00	2.86
Hydrogenated vegetable oil	6.00	0.48
Ethyl cellulose	120.00	9.52
Lubrication Stage		
Calcium carboxymethyl cellulose	60.00	4.76
Croscarmellose sodium	180.00	14.29
Hydrogenated vegetable oil	12.00	0.95

Dissolution profile

<i>Time (hour)</i>	<i>Percent Cefuroxime axetil released</i>
1	41.80
2	64.10
3	75.20
4	81.20
5	86.10

Procedure for making the formulations of examples 16-17

- 5 Cefuroxime axetil, lactose anhydrous, Plasdone S-630, Gelcarin GP911, and a portion of hydrogenated vegetable oil (0.48% w/w), were screened through 40 mesh sieve and roll compacted. The compacts were crushed and passed through 20 mesh to get granules. The resultant granules were coated with ethyl cellulose aqueous dispersion in a fluid bed processor. The resultant dried
- 10 granules were screened and blended with calcium carboxymethyl cellulose, croscarmellose sodium, and remaining hydrogenated vegetable oil (0.95% w/w). The lubricated granules were then compressed into the tablets using a tablet press. The tablets were coated.

Example 18Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefuroxime axetil (Equiv. to 400 mg cefuroxime)	617.55	46.78
Lactose anhydrous	168.45	12.76
Plasdone S-630	60.00	4.55
Gelcarin GP911	36.00	2.73
Hydrogenated vegetable oil	6.00	0.45
Ethyl cellulose	120.00	9.09
Lubrication Stage		
Croscarmellose sodium	300.00	22.73
Hydrogenated vegetable oil	12.00	0.91

Procedure for making the formulation

- 5 Cefuroxime axetil, lactose anhydrous, Plasdone S-630, Gelcarin GP911, and a portion of hydrogenated vegetable oil (0.45% w/w), were screened through 40 mesh sieve and roll compacted. The compacts were crushed and passed through 20 mesh to get granules. The resultant granules were coated with ethyl cellulose aqueous dispersion in a fluid bed processor. The resultant dried
- 10 granules were screened and blended with croscarmellose sodium, and remaining hydrogenated vegetable oil (0.91% w/w). The lubricated granules were then compressed into the tablets using a tablet press. The tablets were coated.

Dissolution profile

<i>Time (hour)</i>	<i>Percent Cefuroxime axetil released</i>
1	52.6
2	72.7

3	82.5
4	87.8
5	90.6

Example 19Composition

<i>Ingredients</i>	<i>Weight (mg/ tablet)</i>	<i>% w/w</i>
Cefuroxime axetil (Equiv. to 400 mg cefuroxime)	617.55	51.46
Lactose anhydrous	84.45	7.04
Croscarmellose sodium	24.00	2.00
Plasdone S-630	60.00	5.00
Gelcarin GP911	36.00	3.00
Hydrogenated vegetable oil	6.00	0.50
Ethyl cellulose	120.00	10.00
Lubrication Stage		
Calcium carboxymethyl cellulose	60.00	5.00
Croscarmellose sodium	180.00	15.00
Hydrogenated vegetable oil	12.00	1.00

5 Procedure for making the formulation

Cefuroxime axetil, lactose anhydrous, croscarmellose sodium, Plasdone S-630, Gelcarin GP911, and a portion of hydrogenated vegetable oil (0.50% w/w), were screened through 40 mesh sieve and roll compacted. The compacts were crushed and passed through 20 mesh to get granules. The resultant granules were coated with ethyl cellulose aqueous dispersion in a fluid bed processor. The resultant dried granules were screened and blended with calcium carboxymethyl cellulose, croscarmellose sodium, and remaining

hydrogenated vegetable oil (1.00% w/w). The lubricated granules were then compressed into the tablets using a tablet press. The tablets were coated.

Bioavailability study

Bioavailability study was done using the composition of Example 1 in normal healthy human volunteers. The study was conducted for comparison between conventional Cefpodoxime tablets 200mg and sustained release Cefpodoxime tablets 400mg.

Six healthy male volunteers were selected for the study in which each volunteer was administered a dose of the drug with 180 ml of water. The volunteers fasted overnight and had a US FDA recommended breakfast before taking the drug. The desired blood levels up to 17 hrs were achieved with the composition prepared according the present invention. The data of the comparative pharmacokinetic parameters are summarized in table below (Figure 1).

Comparative pharmacokinetic parameters:

Parameters	Cefpodoxime 200 mg (Conventional)	Cefpodoxime OD 400 mg
C _{max} (mcg/ml)	2.252	1.418
T _{max} (hrs)	3.083	4.583
AUC _{0-t} (mcg.hr/ml)	14.503	14.027

Description of figure

Figure 1: Plot of comparative plasma profile of Cefpodoxime OD tablets 400mg (Test) v/s Cefpodoxime conventional tablets 200mg (Ref)

Claims:

1. A sustained release oral pharmaceutical composition comprising a beta lactam antibiotic or their pharmaceutically acceptable salts, hydrates or esters; mixture of polymers comprising of a water soluble N-vinyl-2-pyrrolidone/vinyl acetate copolymer and polysaccharide(s); a release enhancer(s); and other pharmaceutically acceptable excipients.
2. The composition according to claim 1, which comprises about 25 to 90% by weight of beta lactam antibiotic or their pharmaceutically acceptable salts, hydrates or esters.
3. The composition according to claim 1, wherein the beta lactam antibiotic is selected from amoxycillin, ampicillin, cephalixin, cefprozil, cefadroxil, cefaclor, cefamandole, cefoxitin, cephalothin, cephapirin, ceftizoxime, cefonicid, cefpodoxime proxetil, cefuroxime axetil, cefotiam hexetil, ceftaram pivoxil, cefditoren pivoxil, cefcapene pivoxil, cefetamet pivoxil or their pharmaceutically acceptable salts, hydrates or esters.
4. The composition according to claim 3, wherein the beta lactam antibiotic is preferably a prodrug ester such as cefpodoxime proxetil, cefuroxime axetil, cefotiam hexetil, ceftaram pivoxil, cefditren pivoxil, cefcapene pivoxil or cefetamet pivoxil.
5. The composition according to claim 4, wherein the beta lactam antibiotic is more preferably selected from cefpodoxime proxetil or cefuroxime axetil.
6. The composition according to claim 1, which comprises a mixture of polymers from about 1 to 35% by weight of the composition.
7. The composition according to claim 1, which comprises from about 1 to 30% of N-vinyl-2-pyrrolidone/vinyl acetate copolymer by weight of the composition.
8. The composition according to claim 1, which comprises from about 0.5 to 20% of carrageenan by weight of the composition.

9. The composition according to claim 1, which comprises release enhancers from about 0.1 to 25% by weight either alone or in combination of the total weight of the composition.
10. The composition according to claim 9, wherein the release enhancer is
5 selected from sodium chloride, potassium chloride; sulfates of sodium, potassium, calcium, magnesium; or lactose, either alone or in combination thereof.
11. The composition according to claim 1, wherein the pharmaceutically acceptable excipients are selected from disintegrants, integrity enhancers,
10 solubilizers, lubricants, diluents, coating agents, and optionally binders.
12. The composition according to claim 11, which comprises from about 0.1 to 10% of integrity enhancer by weight of the composition.
13. The composition according to claim 12, wherein integrity enhancers is
15 selected from polyacrylic acid or its derivatives, such as Carbopol 971P, Carbopol 974P, Novenon AA1 and the like, either alone or in combination thereof.
14. The composition according to claim 11, which comprises from about 0.1 to 15% of disintegrant by weight of the composition.
15. The composition according to claim 14, wherein the disintegrant is
20 selected from croscarmellose sodium, crospovidone, calcium carboxymethyl cellulose, sodium starch glycolate and the like, either alone or in combination thereof.
16. The composition according to claim 11, which comprises from about 0.1 to 10% of solubilizer by weight of the composition.
- 25 17. The composition according to claim 16, wherein the solubliser is selected from pharmaceutically acceptable cationic surfactants like cetrimide, benzalkonium chloride, benzethonium chloride; anionic surfactants like sodium lauryl sulphate, docusate sodium; and non-ionic surfactants like glyceryl monooleate, polyoxyethylene sorbitan fatty acid, polyoxyethylene

sorbitan fatty esters, polyvinyl alcohol or sorbitan esters, either alone or in combination thereof.

18. The composition according to claim 11, which comprises lubricant from about 0.2 % to about 5% by weight of the total weight of the composition, used either alone or in combination.

19. The composition according to claim 18, wherein the lubricant is selected from talc, stearic acid, magnesium stearate, colloidal silicon dioxide, calcium stearate, zinc stearate or hydrogenated vegetable oil.

20. The composition according to claim 11, which comprises diluents in an amount from about 1 to about 40% by weight of the composition.

21. The composition according to claim 20, wherein the diluent is a water soluble or water dispersible diluent.

22. The composition according to claim 21, wherein the water soluble diluent is selected from mannitol, glucose, sorbitol, maltose, dextrans, dextrans or dextrans, either alone or in combination thereof.

23. The composition according to claim 21, wherein the water dispersible diluent is selected from carboxymethyl cellulose, calcium carboxymethyl cellulose, microcrystalline cellulose or pregelatinized starch, either alone or in combination thereof.

24. The composition according to claim 11, which comprises from about 0.1 to 20% of binder by weight of the composition.

25. The composition according to claim 24, wherein the binder is selected from cellulosic ether such as methyl cellulose, hydroxy propyl cellulose, hydroxy ethyl cellulose, hydroxy propyl methyl cellulose or ethyl cellulose, polyvinyl pyrrolidone and its derivatives or copolymers, either alone or in combination thereof.

26. The composition according to claim 11, wherein the coating agent comprises of film forming agents such as hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose; plasticizers such as

propylene glycol, polyethylene glycol; color pigments; optionally opacifiers such as titanium dioxide; and optionally talc.

27. The composition according to claim 1, wherein the polysaccharide is selected from different grades of carrageenan such as Viscarin GP328,
5 Viscarin GP 209, and Gelcarin GP911, used either alone or in combination thereof.

28. A sustained release oral pharmaceutical composition comprising a beta lactam antibiotic or their pharmaceutically acceptable salts, hydrates or esters; mixture of polymers comprising of a water soluble N-vinyl-2-
10 pyrrolidone/vinyl acetate copolymer and polysaccharide(s); a release enhancer(s); and other pharmaceutically acceptable excipients combined with a beta lactamase inhibitor.


29. The composition according to claim 28, where in the beta lactamase inhibitor is selected from clavulonic acid, sulbactam, tazobactam or their
15 pharmaceutically acceptable salts, hydrates or esters.

30. A process for the preparation of the sustained release pharmaceutical composition, the said method comprising the steps of:

- (i) blending the beta lactam antibiotic or its pharmaceutically acceptable salts, hydrates or esters, diluent(s) and copolymer; polysaccharide(s),
20 disintegrant(s) and lubricant(s) either whole or in part; release enhancer(s); optionally integrity enhancer(s) and solubilizer(s) together,
- (ii) passing the blended mixture through a suitable sieve,
- (iii) compacting the blend using a roller compactor,
- (iv) sizing the compacted material using a suitable mill,
- 25 (v) blending the resultant granules with lubricant(s) in whole or in part; optionally with polysaccharide(s), release enhancer(s), and integrity enhancer(s), in whole or in part,
- (vi) compressing the lubricated granules using a tableting machine and,
- (vii) coating the tablets.

31. A process for the preparation of the sustained release pharmaceutical composition, the said method comprising the steps of:
- (i) blending the beta lactam antibiotic or their pharmaceutically acceptable salts, hydrates or esters, diluent(s), copolymer and polysaccharide(s);
5 disintegrant(s) and lubricant(s) either whole or in part; release enhancer(s); optionally integrity enhancer(s) and solubilizer(s) together,
 - (ii) passing the blended mixture through a suitable sieve,
 - (iii) compacting the blend using a roller compactor,
 - (iv) sizing the compacted material using an suitable mill,
 - 10 (v) resultant granules coated with ethyl cellulose in a suitable fluid bed processor
 - (vi) optionally sizing the coated granules by passing through a suitable sieve
 - (vii) blending the resultant granules with lubricant(s) and disintegrant(s)
 - 15 (viii) compressing the lubricated granules using a tableting machine and
 - (ix) coating the tablets.

1/1



PCT REQUEST

640/MAS/02



Original (for SUBMISSION) - printed on 29.08.2003 05:11:14 PM

		I hereby acknowledge the duty to disclose information that is known by me to be material to patentability as defined by 37 C.F.R. § 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the PCT international filing date of the continuation-in-part application. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.
VIII-4-1-1-1	Name:	KSHIRSAGAR, Rajesh, Suresh
VIII-4-1-1-2	Residence: (city and either US State, if applicable, or country)	Chennai, India
VIII-4-1-1-3	Mailing address:	10th Cross Street, Shastrinagar, Adyar,
VIII-4-1-1-4	Citizenship:	IN
VIII-4-1-1-5	Inventor's Signature: (if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent)	
VIII-4-1-1-6	Date: (of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)	4.9.03

PCT REQUEST

640/MAS/02

Original (for SUBMISSION) - printed on 29.08.2003 05:11:14 PM

VIII-4-1-2-1	Name:	DEVARAJAN, Sampath, Kumar
VIII-4-1-2-2	Residence: (city and either US State, if applicable, or country)	Chennai, India
VIII-4-1-2-3	Mailing address:	Saidapet,
VIII-4-1-2-4	Citizenship:	IN
VIII-4-1-2-5	Inventor's Signature: (if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent)	
VIII-4-1-2-6	Date: (of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)	4/9/03
VIII-4-1-3-1	Name:	JINDAL, Kour, Chand
VIII-4-1-3-2	Residence: (city and either US State, if applicable, or country)	Haryana, India
VIII-4-1-3-3	Mailing address:	Sector - 9, Panchkula,
VIII-4-1-3-4	Citizenship:	IN
VIII-4-1-3-5	Inventor's Signature: (if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent)	
VIII-4-1-3-6	Date: (of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)	Sept 15, 2003